Archives

by in
Entry Author Date Location
Alkermes Nabs $250M It Doesn’t Need, But Could Fend Off Barbarians 01/13/14 Boston
What Biotech Pros Will Be Chirping About at JP Morgan This Week 01/13/14 National
East Coast Biotech Roundup: Gerngross, Akili, Intercept, & More 01/10/14 Boston
Sangamo, Biogen Team up to Make Drugs For Blood Disorders 01/09/14 San Francisco
Tillman Gerngross, the Scientist Turned Scientific Businessman 01/09/14 Boston
East Coast Biotech Roundup: Scholar Rock, Dicerna, Eleven, & More 01/03/14 Boston
Remembering James L. Vincent, Longtime Biogen Leader 12/31/13 Boston
East Coast Biotech Roundup: ASH, Proteostasis, Retrophin, & More 12/13/13 Boston
Proteostasis, Biogen Team up on Protein Homeostasis Drugs 12/09/13 Boston
Armo BioSciences Joins the Cancer Immunotherapy Party With $20M 11/25/13 San Francisco
East Coast Biotech Roundup: Moderna, Aileron, Seres, & More 11/22/13 Boston
Hologic, Fending off Icahn, Adopts Poison Pill to Deflect Takeover 11/21/13 Boston
How Alkermes Survived a Brush With Death 11/11/13 National
Genentech Does it Again, Wins FDA Approval for ‘Son of Rituxan’ 11/01/13 San Francisco
East Coast Life Sciences Roundup: Foundation, Ophthotech, Sato, & More 09/27/13 Boston
Don’t Be Naïve: 7 Things to Know Before Taking a Biotech Startup Job 09/16/13 National
East Coast Life Sciences Roundup: Genocea, Biogen, OvaScience, & More 09/13/13 Boston
San Diego Life Sciences Roundup: Isis, Neurocrine, MEI, and More 09/12/13 San Diego
Amicus, Biogen Team Up on Parkinson’s Drug Deal 09/10/13 Boston
Disappointments, New Prospects for Rigel Pharmaceuticals 09/10/13 San Francisco
Biogen Idec Strikes $100M Upfront Deal With Isis for Neurology 09/09/13 Boston
Adimab Teams Up With Celgene, Innovent, in Latest Partnership Deals 08/20/13 Boston
Sage Taps Former Shire Exec to Lead CNS Drugs Into Clinical Trials 08/14/13 Boston
East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More 07/26/13 Boston
Adimab Turns Cash Flow Positive With GSK, Biogen Tech Transfer Deals 07/26/13 Boston
Biogen’s Oral MS Drug Tops Estimates, Brings in $192M in First Quarter 07/25/13 Boston
The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts 07/22/13 National
Alkermes Adds Cancer, MS Drugs To Growing Portfolio 07/17/13 Boston
While I Was Away on Denali: NanoString, Mirabilis, Seattle Genetics 07/03/13 Seattle
Constructing Innovation Supply Chains for the Pharmaceutical Industry 06/26/13 Boston
Page 2 of 17 « previous page · next page »